Researchers develop test to predict Alzheimer’s disease years before diagnosis
January 30, 2023Medical Communications
Researchers at King’s College London’s Institute of Psychiatry, Psychology & Neuroscience (IoPPN) have developed a blood test which can potentially …
Chiesi Farmaceutici hires new CEO after $1.48bn Amryst acquisition
January 30, 2023Business Services
Chiesi Farmaceutici, a family-owned Italian pharmaceutical company, has appointed Giuseppe Accogli as group CEO. This comes after 2020’s $1.48bn acquisition …
FDA refuses to regulate CBD, calling on Congress to take charge
January 27, 2023Medical Communications
The FDA is calling on the US Congress to work with them on a new regulatory pathway for cannabidiol (CBD). …
FDA pulls approval of COVID-19 antibody treatment due to inefficacy against variants
January 27, 2023Medical Communications
The FDA has revoked its approval of AstraZeneca’s Evusheld due to the fact that it is not effective against more …
Ipsen reports CHMP negative review for use of palovarotene in EU
January 27, 2023Research and Development
Ipsen, a biopharmaceutical company focused on medicines in oncology, rare diseases and neuroscience, have been denied marketing authorisation by the …
IsoChemiX develop molecules to speed up R&D process
January 27, 2023Research and Development
UK-based pharmaceutical drug discovery company IsoChemiX is developing molecules which will have the ability to cut both the time and …
AI finds liver cancer drug candidate in only 30 days
January 26, 2023Research and Development
With most drug discovery and development processes taking years, if not decades, a team of scientists have broken records with …
Merck’s London research hub to begin construction in April 2023
January 26, 2023Business Services
Merck has been planning a $1.3bn, 220,000 square foot research hub in London for six years but will finally begin …
iNtRON confirms efficacy of ‘Inhalation Anthrax’-fighting drug
January 26, 2023Medical Communications
iNtRON, a bio-new drug developing venture company, has announced the completion of an efficacy evaluation study of BAL200. It has …
Cell BioEngines announces exclusive licencing agreement for cancer cure
January 26, 2023Medical Communications
US-based cell and gene therapy company Cell BioEngines has announced its exclusive licencing agreement with Icahn School of Medicine at …
t.bio chooses Automata as partner for automating a key aspect of its production of iPSC derived human cells
January 26, 2023Business Services
26th January 2023, London UK – Automata, a leading robotics and automation company powering life sciences labs, today announced it …
Orbsen Therapeutics announces encouraging interim results from the NEPHSTROM proof of concept clinical study evaluating ORBCEL™ cell therapy in patients with diabetes and advanced chronic kidney disease
January 26, 2023Business Services
26 January 2023 Galway, Ireland – Orbsen Therapeutics Limited (“Orbsen”), a global leader in stromal cell immunotherapies, today announces encouraging …
First CAR T-cell therapy recommended for routine use on the NHS in England
January 26, 2023Business Services
26th JANUARY 2023, LONDON, UK – Gilead Sciences Ltd. and Kite, a Gilead company, today announced that the National Institute …
Full year revenue and EBITDA in line with guidance Remain focused on post-COVID-19 growth strategy to become a leading global clinical diagnostics company in infectious diseases
January 26, 2023Business Services
Paris, France and Eastleigh, UK – 26 January 2023 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in …
Brits Living with Diabetes Feel Stigma and Bias Impact Their Ability to Manage Their Condition
January 26, 2023Business Services
MAIDENHEAD, BERKSHIRE – TUESDAY 24 JANUARY 2023 – With diabetes prevalence expected to reach almost 5.5 million across the UK …
US Center for Disease Control (CDC) and two major medical journals cite the importance of decolonization in preventing surgical site infections
January 25, 2023Business Services
Brighton, United Kingdom – 25 January 2023 – Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on …
Vertex and CRISPR Therapeutics Announce EMA Marketing Authorization Application Validation for CRISPR/Cas9 GeneEdited Therapy, exagamglogene autotemcel (exa
January 25, 2023Business Services
LONDON, UK and ZUG, Switzerland, January 25, 2023 – Vertex Pharmaceuticals (Europe) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that …
STORM Therapeutics Presents STC-15 Preclinical Data Supporting Treatment of Patients with AML at the AACR Acute Myeloid Leukemia and Myelodysplastic Syndrome Conference
January 25, 2023Business Services
25 January 2023, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage biotechnology company discovering and developing novel small molecule …
Scancell Holdings plc: Interim Results for the 6 months ended 31 October 2022
January 25, 2023Business Services
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announces …
Sosei Heptares Webinar Presentation for FY2022 Financial Results
January 25, 2023Business Services
Tokyo, Japan and Cambridge, UK, 25 January 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
